Health

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 17:06:24 UTC.

Briefings

Novartis's remibrutinib treatment significantly reduced relapse rates in multiple sclerosis trials, cutting the annualized relapse rate by 35.2% compared to Sanofi's Aubagio in Phase 3 studies. Heinz Wiendl, a neurologist at the University of Freiburg, presented these findings at an MS conference in Toronto. While Roche's fenebrutinib showed a larger 50% relapse reduction against Aubagio, remibrutinib offers a cleaner safety profile, potentially making it competitive in the market.

Key points

• Novartis's remibrutinib reduced the annualized relapse rate by 35.2% in Phase 3 studies against Sanofi's Aubagio.
• Heinz Wiendl, a neurologist at the University of Freiburg, presented these findings at an MS conference in Toronto.

Context

This finding is significant as it highlights a potential competitive advantage for remibrutinib due to its safety profile, even though its efficacy margin is narrower than Roche's fenebrutinib.

Limitations

Data is limited to two Phase 3 studies in relapsing MS; efficacy comparison is against Sanofi's Aubagio, not Roche's fenebrutinib. Specific trial numbers, patient counts, and exact dates are not provided in the evidence.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 17:07:39 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeibqwq7ywjueuxik2fsybzv6ehuuyb4tyaaldt5dxckrixilsp64um